Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) CEO August Troendle sold 1,983 shares of the stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $620.23, for a total transaction of $1,229,916.09. Following the completion of the transaction, the chief executive officer directly owned 545,217 shares in the company, valued at $338,159,939.91. The trade was a 0.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Medpace Price Performance
MEDP stock opened at $614.06 on Wednesday. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The stock has a market capitalization of $17.14 billion, a price-to-earnings ratio of 35.99, a PEG ratio of 2.77 and a beta of 1.15. The business's fifty day moving average price is $556.26 and its two-hundred day moving average price is $492.77.
Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. The firm had revenue of $707.33 million during the quarter, compared to analysts' expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company's quarterly revenue was up 17.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current year.
Key Headlines Impacting Medpace
Here are the key news stories impacting Medpace this week:
- Positive Sentiment: Medpace’s latest quarterly results were strong: earnings of $4.25 per share exceeded the $3.98 consensus estimate, while revenue rose 17.2% year over year to $707.33 million, ahead of expectations. Management’s fiscal 2026 EPS guidance is $17.25–$17.95. Institutional ownership is also high at approximately 78%, with several large investors adding positions.
- Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day days-to-cover ratio. Because the figures show no measurable short position, they provide little indication of near-term buying or selling pressure.
- Neutral Sentiment: Analyst sentiment remains mixed. The consensus rating is “Hold,” with an average price target of $584.18, below recent trading levels. BMO Capital Markets raised its target to $600 while maintaining a market-perform rating, and Weiss Ratings upgraded the stock to “Buy.”
- Negative Sentiment: Multiple company insiders recently sold shares. CEO August J. Troendle sold 13,995 shares for approximately $8.74 million on August 21 and another 1,983 shares for about $1.23 million on August 24. CFO Kevin Brady sold 3,400 shares worth roughly $2.13 million, reducing his ownership by 20.95%. Additional director sales were also reported. Although executives retain significant holdings, the concentration of selling can weigh on investor confidence.
Hedge Funds Weigh In On Medpace
Several institutional investors have recently added to or reduced their stakes in the business. BOKF NA grew its holdings in shares of Medpace by 0.8% in the third quarter. BOKF NA now owns 2,542 shares of the company's stock valued at $1,307,000 after purchasing an additional 20 shares during the period. Valeo Financial Advisors LLC boosted its position in shares of Medpace by 5.0% during the 4th quarter. Valeo Financial Advisors LLC now owns 444 shares of the company's stock worth $249,000 after purchasing an additional 21 shares during the period. UMB Bank n.a. grew its stake in shares of Medpace by 5.6% in the fourth quarter. UMB Bank n.a. now owns 450 shares of the company's stock valued at $253,000 after buying an additional 24 shares in the last quarter. Schulhoff & Co. Inc. grew its position in Medpace by 1.1% in the 4th quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company's stock valued at $1,237,000 after acquiring an additional 25 shares in the last quarter. Finally, Balefire LLC boosted its stake in shares of Medpace by 6.1% in the first quarter. Balefire LLC now owns 451 shares of the company's stock valued at $217,000 after purchasing an additional 26 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several equities research analysts recently weighed in on MEDP shares. Truist Financial raised their price objective on Medpace from $462.00 to $609.00 and gave the company a "hold" rating in a report on Friday, July 24th. Royal Bank Of Canada raised their price target on shares of Medpace from $484.00 to $692.00 and gave the stock an "outperform" rating in a report on Friday, July 24th. Weiss Ratings upgraded shares of Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, August 12th. Robert W. Baird upped their price objective on shares of Medpace from $547.00 to $624.00 and gave the company a "neutral" rating in a research note on Friday, July 24th. Finally, Mizuho increased their price objective on shares of Medpace from $586.00 to $665.00 and gave the stock an "outperform" rating in a research report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Medpace has an average rating of "Hold" and an average price target of $584.18.
View Our Latest Stock Analysis on Medpace
About Medpace
(
Get Free Report)
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
